BioDelivery Sciences International, Inc. (NASDAQ:BDSI) – Analysts at Cantor Fitzgerald upped their FY2017 earnings per share (EPS) estimates for shares of BioDelivery Sciences International in a note issued to investors on Sunday. Cantor Fitzgerald analyst L. Chen now anticipates that the specialty pharmaceutical company will earn $0.15 per share for the year, up from their previous estimate of $0.14. Cantor Fitzgerald has a “Buy” rating and a $5.00 price target on the stock.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.01. BioDelivery Sciences International had a net margin of 10.40% and a return on equity of 33.83%. The business had revenue of $11.25 million for the quarter, compared to the consensus estimate of $9.40 million. During the same quarter in the previous year, the firm earned ($0.30) earnings per share. The company’s revenue for the quarter was up 215.1% on a year-over-year basis.

WARNING: This story was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/11/14/biodelivery-sciences-international-inc-forecasted-to-earn-fy2017-earnings-of-0-15-per-share-bdsi.html.

Other equities analysts also recently issued research reports about the stock. Roth Capital set a $5.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a report on Monday. Piper Jaffray Companies set a $4.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a report on Sunday, October 22nd. HC Wainwright set a $5.00 price target on shares of BioDelivery Sciences International and gave the company a “buy” rating in a report on Friday, October 13th. Janney Montgomery Scott lifted their price target on shares of BioDelivery Sciences International from $3.00 to $4.00 and gave the company a “fair value” rating in a report on Monday, July 24th. Finally, Zacks Investment Research downgraded shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $4.29.

BioDelivery Sciences International (NASDAQ:BDSI) opened at $2.60 on Tuesday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.28 and a quick ratio of 1.07. BioDelivery Sciences International has a 1-year low of $1.50 and a 1-year high of $3.60.

Institutional investors have recently added to or reduced their stakes in the company. Advisor Group Inc. raised its position in shares of BioDelivery Sciences International by 42.1% during the second quarter. Advisor Group Inc. now owns 45,066 shares of the specialty pharmaceutical company’s stock valued at $126,000 after buying an additional 13,341 shares during the last quarter. Valley National Advisers Inc. raised its position in shares of BioDelivery Sciences International by 59.0% during the second quarter. Valley National Advisers Inc. now owns 37,715 shares of the specialty pharmaceutical company’s stock valued at $106,000 after buying an additional 14,000 shares during the last quarter. Stonepine Capital Management LLC raised its position in shares of BioDelivery Sciences International by 22.2% during the second quarter. Stonepine Capital Management LLC now owns 3,477,673 shares of the specialty pharmaceutical company’s stock valued at $9,737,000 after buying an additional 632,853 shares during the last quarter. KCG Holdings Inc. raised its position in shares of BioDelivery Sciences International by 469.9% during the first quarter. KCG Holdings Inc. now owns 110,728 shares of the specialty pharmaceutical company’s stock valued at $210,000 after buying an additional 91,297 shares during the last quarter. Finally, GSA Capital Partners LLP raised its position in shares of BioDelivery Sciences International by 10.1% during the second quarter. GSA Capital Partners LLP now owns 488,767 shares of the specialty pharmaceutical company’s stock valued at $1,369,000 after buying an additional 44,700 shares during the last quarter. Hedge funds and other institutional investors own 40.68% of the company’s stock.

In other news, CEO Mark A. Sirgo sold 65,405 shares of BioDelivery Sciences International stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $2.75, for a total transaction of $179,863.75. Following the sale, the chief executive officer now owns 1,509,262 shares in the company, valued at $4,150,470.50. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Mark A. Sirgo sold 201,373 shares of BioDelivery Sciences International stock in a transaction that occurred on Thursday, September 21st. The shares were sold at an average price of $2.84, for a total transaction of $571,899.32. Following the sale, the insider now owns 1,509,262 shares in the company, valued at approximately $4,286,304.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 402,127 shares of company stock worth $1,142,798. Company insiders own 7.73% of the company’s stock.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.